Targovax ASA: Third quarter 2019 results
Oslo, Norway, 7 November 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2019 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below). HIGHLIGHTS FOR THE THIRD QUARTER 2019 · Targovax announced data from part 1 of the ONCOS-102 trial in checkpoint inhibitor refractory advanced melanoma, showing validated clinical responses in three out of nine patients (33% ORR), including one patient with a complete